ArticleJournal of translational medicine2026
Biomimetic nanoplatform M-MPDA@CeO2 coated with macrophage membrane in acute lung injury: characterization and function evaluation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Macrophage Membrane-Camouflaged Mesoporous Polydopamine Nanoparticles for Targeted Delivery of Apigenin in Sepsis-Induced Acute Lung Injury.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The pathogenesis of acute lung injury (ALI) is characterized by a dysregulated hyperinflammatory cascade initiated by activated pulmonary macrophages. Conventional nanoparticles exhibit limited therapeutic efficacy in ALI due to their insufficient penetration across the pulmonary mucus barrier and inability to inhibit the exacerbated inflammatory cascade within the pathogenic microenvironment. To address these limitations, this study developed a novel macrophage membrane-biomimetic nano-delivery system designed to enhance biocompatibility, achieve targeted delivery to inflammatory sites, and exert synergistic antioxidant effects. The nanocomposite was constructed by loading cerium dioxide (CeO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.